Platelet-leukocyte hybrid membrane-coated immunomagnetic beads and preparation method and application thereof

Abstract

The invention discloses a platelet-leukocyte hybrid membrane-coated immunomagnetic beads and a preparation method and an application thereof. Magnetic beads were coated by using a hybrid membrane of platelet (PLT)-white blood cells (WBC), and then the surface thereof is modified with circulating tumor cells (CTCs)-specific antibodies to obtain PLT-WBC hybrid membrane-coated immunomagnetic beads (HM-IMBs). HM-IMBs inherit the enhanced CTC-binding ability from PLT and the ability to reduce homologous WBC interactions from WBC, therefore, the efficiency and the purity of the cell separation is effectively increased. According to the use of the HM-IMBs, 16 CTCs in clinical blood samples collected from patients with colorectal cancer, breast cancer, or gastric cancer were successfully identified, and the purity of isolated CTCs was greater than 85%. Therefore, this liquid biopsy tool will open up new areas of technology for cancer diagnosis and treatment.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and mainly relates to a platelet-leukocyte mixed membrane-coated immune magnetic bead, a preparation method and application thereof. Background technique [0002] Circulating tumor cells (CTCs) are malignant cells that enter the circulation from solid tumors and have proven to be important in early detection, monitoring and prognosis of cancer. To date, various platforms have been developed to selectively isolate CTCs from circulation, including immunomagnetic beads (IMBs), antibody-conjugated nanostructures, and some methods based on their physical properties. Among them, the IMBs method using magnetic beads (MBs) as the separation medium and antibodies that specifically bind to CTCs on MBs are the most commonly used methods. Due to the extremely rare number of circulating tumor cells in peripheral blood, the capture efficiency and purity have always been important factors limiting the rese...

AI Technical Summary

Problems solved by technology

Due to the extremely rare number of circulating tumor cells in peripheral blood, the capture efficiency and purity have always been important factors that limit the research on circulating tumor cells. At present, most methods cannot achieve high efficiency and high purity capture and detection at the same time.

The CellSearch system is currently the only method approved by the U.S. Food and Drug Administration (FDA) to detect circulating tumor cells. Although it can achieve capture and detection, the cell recovery rate of the system in spiked blood samples is only about 40%, and Samples still contain 1000-3000 white blood cells (WBC) per milliliter, resulting in less than 0.5% purity and are expensive

Images